Literature DB >> 32761725

NIR-Absorbing RuII Complexes Containing α-Oligothiophenes for Applications in Photodynamic Therapy.

Liubov M Lifshits1, John A Roque1,2, Houston D Cole1, Randolph P Thummel3, Colin G Cameron1, Sherri A McFarland1,2.   

Abstract

The design of near-infrared (NIR)-active photosensitizers (PSs) for light-based cancer treatments such as photodynamic therapy (PDT) has been a challenge. While several NIR-RuII scaffolds have been reported, this approach has not been proven in cells. This is the first report of NIR-RuII PSs that are phototoxic to cancer cells, including highly pigmented B16F10 melanoma cells. The PS family incorporated a bis(1,8-naphthyridine)-based ligand (tpbn), a bidentate thiophene-based ligand (nT; n=0-4), and a monodentate 4-picoline ligand (4-pic). All compounds absorbed light >800 nm with maxima near 730 nm. Transient absorption (TA) measurements indicated that n=4 thiophene rings (4T) positioned the PDT-active triplet intraligand charge transfer (3 ILCT) excited state in energetic proximity to the lowest-lying triplet metal-to-ligand charge transfer (3 MLCT). 4T had low-micromolar phototoxicity with PIvis and PI733nm values as large as 90 and 12, respectively. Spectroscopic studies suggested that the longer-lived (τTA =3-6 μs) 3 ILCT state was accessible from the 3 MLCT state, but energetically uphill in the overall photophysics. The study highlights that phototoxic effects can be achieved with NIR-absorbing RuII PSs as long as the reactive 3 ILCT states are energetically accessible from the low-energy 3 MLCT states. It also demonstrates that tissue-penetrating NIR light can be used to activate the PSs in highly pigmented cells where melanin attenuates shorter wavelengths of light.
© 2020 Wiley-VCH GmbH.

Entities:  

Keywords:  intraligand charge-transfer; melanoma; near-infrared (NIR) photosensitizers; photodynamic therapy; ruthenium anticancer agents

Mesh:

Substances:

Year:  2020        PMID: 32761725      PMCID: PMC7736147          DOI: 10.1002/cbic.202000419

Source DB:  PubMed          Journal:  Chembiochem        ISSN: 1439-4227            Impact factor:   3.164


  44 in total

1.  Eilatin complexes of ruthenium and osmium. synthesis, electrochemical behavior, and near-IR luminescence.

Authors:  Sheba D Bergman; Dalia Gut; Moshe Kol; Cristiana Sabatini; Andrea Barbieri; Francesco Barigelletti
Journal:  Inorg Chem       Date:  2005-10-31       Impact factor: 5.165

2.  1H, 13C, 15N NMR coordination shifts in Fe(II), Ru(II) and Os(II) cationic complexes with 2,2':6',2″-terpyridine.

Authors:  Leszek Pazderski; Tomasz Pawlak; Jerzy Sitkowski; Lech Kozerski; Edward Szlyk
Journal:  Magn Reson Chem       Date:  2011-03-29       Impact factor: 2.447

3.  Synthesis, Characterization and Photobiological Studies of Ru(II) Dyads Derived from α-Oligothiophene Derivatives of 1,10-Phenanthroline.

Authors:  Susan Monro; Colin G Cameron; Xiaolin Zhu; Katsuya L Colón; Huimin Yin; Tariq Sainuddin; Marc Hetu; Mitch Pinto; Anderson Fuller; Leah Bennett; John Roque; Wenfang Sun; Sherri A McFarland
Journal:  Photochem Photobiol       Date:  2018-10-27       Impact factor: 3.421

Review 4.  The Course of Immune Stimulation by Photodynamic Therapy: Bridging Fundamentals of Photochemically Induced Immunogenic Cell Death to the Enrichment of T-Cell Repertoire.

Authors:  Shubhankar Nath; Girgis Obaid; Tayyaba Hasan
Journal:  Photochem Photobiol       Date:  2019-11-10       Impact factor: 3.421

5.  Transition Metal Complexes and Photodynamic Therapy from a Tumor-Centered Approach: Challenges, Opportunities, and Highlights from the Development of TLD1433.

Authors:  Susan Monro; Katsuya L Colón; Huimin Yin; John Roque; Prathyusha Konda; Shashi Gujar; Randolph P Thummel; Lothar Lilge; Colin G Cameron; Sherri A McFarland
Journal:  Chem Rev       Date:  2018-10-08       Impact factor: 60.622

6.  Photo-Uncaging of a Microtubule-Targeted Rigidin Analogue in Hypoxic Cancer Cells and in a Xenograft Mouse Model.

Authors:  Vincent H S van Rixel; Vadde Ramu; Austin B Auyeung; Nataliia Beztsinna; David Y Leger; Lucien N Lameijer; Stan T Hilt; Sylvia E Le Dévédec; Tugba Yildiz; Tania Betancourt; M Brenton Gildner; Todd W Hudnall; Vincent Sol; Bertrand Liagre; Alexander Kornienko; Sylvestre Bonnet
Journal:  J Am Chem Soc       Date:  2019-11-06       Impact factor: 15.419

7.  Development of photodynamic therapy regimens that control primary tumor growth and inhibit secondary disease.

Authors:  Madeeha Shams; Barbara Owczarczak; Patricia Manderscheid-Kern; David A Bellnier; Sandra O Gollnick
Journal:  Cancer Immunol Immunother       Date:  2014-11-11       Impact factor: 6.968

8.  Reprogramming human A375 amelanotic melanoma cells by catalase overexpression: Upregulation of antioxidant genes correlates with regression of melanoma malignancy and with malignant progression when downregulated.

Authors:  Candelaria Bracalente; Irene L Ibañez; Ariel Berenstein; Cintia Notcovich; María B Cerda; Fabio Klamt; Ariel Chernomoretz; Hebe Durán
Journal:  Oncotarget       Date:  2016-07-05

9.  Achieving efficient photodynamic therapy under both normoxia and hypoxia using cyclometalated Ru(ii) photosensitizer through type I photochemical process.

Authors:  Zhuang Lv; Huanjie Wei; Qing Li; Xianlong Su; Shujuan Liu; Kenneth Yin Zhang; Wen Lv; Qiang Zhao; Xianghong Li; Wei Huang
Journal:  Chem Sci       Date:  2017-10-31       Impact factor: 9.825

Review 10.  Combination of photodynamic therapy (PDT) and anti-tumor immunity in cancer therapy.

Authors:  Hee Sook Hwang; Heejun Shin; Jieun Han; Kun Na
Journal:  J Pharm Investig       Date:  2018-11-01
View more
  3 in total

1.  Ruthenium Photosensitizers for NIR PDT Require Lowest-Lying Triplet Intraligand (3IL) Excited States.

Authors:  Liubov M Lifshits; John A Roque; Elamparuthi Ramasamy; Randolph P Thummel; Colin G Cameron; Sherri A McFarland
Journal:  J Photochem Photobiol       Date:  2021-09-15

2.  Intraligand Excited States Turn a Ruthenium Oligothiophene Complex into a Light-Triggered Ubertoxin with Anticancer Effects in Extreme Hypoxia.

Authors:  John A Roque Iii; Houston D Cole; Patrick C Barrett; Liubov M Lifshits; Rachel O Hodges; Susy Kim; Gagan Deep; Antonio Francés-Monerris; Marta E Alberto; Colin G Cameron; Sherri A McFarland
Journal:  J Am Chem Soc       Date:  2022-04-28       Impact factor: 16.383

Review 3.  Photodynamic Therapy for Basal Cell Carcinoma: The Clinical Context for Future Research Priorities.

Authors:  Nicholas J Collier; Lesley E Rhodes
Journal:  Molecules       Date:  2020-11-18       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.